Earn CME for related activities: www.naccme.com/oln
In this presentation from the 'FLT3 Targets in RIn this presentation from the 'R AML: Evaluating Emerging Clinical Data and Implications on Current Practice’ symposium, Dr. Gail J. Roboz discusses minimal residual disease in acute myeloid leukemia (AML).
© 2018 Imedex, an HMP Company
Негізгі бет MRD in AML: What is it and what do I do about it?
Пікірлер: 4